-
Jefferies Raises PT On PODD To $24
Tuesday, May 10, 2011 - 8:26am | 98Jefferies is raising its price target on Insulet Corp. (NASDAQ: PODD) from $20 to $24 after the company submitted an application to the FDA. In the report, Jefferies explains, “Insulet released 1Q results of $28.3mn on par with expectations reflecting seasonal softness as insurance deductibles...
-
Benzinga's Top Upgrades (MR, SKS, CPN, ROSE)
Tuesday, May 10, 2011 - 8:14am | 131Oppenheimer upgraded Mindray Medical International Ltd (NYSE: MR) from “perform” to “outperform.” MR's shares closed at $27.54 yesterday. Mindray Medical's PEG ratio is 0.88. Analysts at Goldman Sachs upgraded Saks Inc (NYSE: SKS) from “sell” to “neutral.” SKS' shares closed at $11.32 yesterday....
-
Oppenheimer Has Outperform On Mindray Medical Following Earnings (MR)
Tuesday, May 10, 2011 - 8:11am | 154Oppenheimer & Co. has an Outperform rating and a $28 price target on shares of Mindray Medical Int'l Ltd. (NYSE: MR) following earnings. In a note to investors, Oppenheimer writes, "Mindray reported 1Q11 revenue of $180.9M, beating the Street and our estimates of $168M. International sales...
-
Morgan Stanley Reports on Mindray Medical (MR)
Tuesday, May 10, 2011 - 7:48am | 145In a report released today, Morgan Stanley commented on Mindray Medical (NYSE: MR). In the report, Morgan Stanley was bullish on the company. Morgan Stanley writes, “Mindray reported 1Q results with revenue beating but EPS missing our estimates on higher than expected operating expenses. MR saw...
-
UPDATE: Jefferies Raises PT on Insulet to $24 (PODD)
Tuesday, May 10, 2011 - 7:44am | 70Jefferies is out with its report today on Insulet (NASDAQ: PODD), raising its PT from $20 to $24. In a note to clients, Jefferies writes, "As profitability is emerging, EV/Sales is the best valuation method. We use the 6.4x current multiple rolled forward to 2012 EV/Sales to arrive at a $24/share...
-
Jefferies Raises PT On Insulet Corporation To $24
Tuesday, May 10, 2011 - 6:58am | 27Jefferies & Company has raised the price target on Insulet Corporation (NASDAQ: PODD) from $20 to $24 and maintains Its Buy rating.
-
Oppenheimer Upgrades Mindray Medical To Outperform, $32 PT
Tuesday, May 10, 2011 - 5:55am | 25Oppenheimer has upgraded Mindray Medical (NYSE: MR) from Perform to Outperform and has established a $32 price target.
-
Biotech Stock News; Q1 Publishing Research Featuring Verisante Technology, Inc.
Monday, May 9, 2011 - 3:30pm | 2684May 9, 2011 - Investorideas.com newswire; The following biotech stock report is issued by Q1 Publishing Research covering Verisante Technology, Inc. (TSX-V: VRS) (PINK SHEETS: VRSEF). Investorideas.com Newswire features third party research and equity reports from multiple research firms in the...
-
NASDAQ Stocks Hitting 52-Week Highs (PSMT, KLIC, OFIX, JCS)
Monday, May 9, 2011 - 10:18am | 138PriceSmart Inc (NASDAQ: PSMT) shares surged 4.41% to create a new 52-week high of $46.84. PSMT reported a 37.0% y/y surge in its April net sales. Kulicke and Soffa Industries Inc (NASDAQ: KLIC) shares jumped 2.09% to create a new 52-week high of $12.23. KLIC reported upbeat Q2 earnings. Orthofix...
-
MELA Sciences Submits a Citizen Petition to FDA Commissioner Calling for Enforcement of Binding Protocol Agreement and FDA Laws and Regulations in PMA Review of MelaFind
Monday, May 9, 2011 - 9:29am | 59MELA Sciences (NASDAQ: MELA) today announced that it has submitted a Citizen Petition with the U.S. Food and Drug Administration, requesting that Margaret Hamburg, MD, Commissioner of the FDA, enforce its binding protocol agreement as well as FDA laws and regulations in the review of the MelaFind®...
-
Oppenheimer Gives Earnings Preview On Medtronic; Raises PT To $48
Monday, May 9, 2011 - 9:16am | 203Medtronic's (NYSE: MDT) F4Q11 results are due May 24. FY12 guidance will also be provided. Oppenheimer looks for accelerated FY12 sales and EPS growth after a tough FY11 led by several recent key product launches. Sales will also benefit from easier comps and a much stronger FX tailwind based on...
-
Hill Rom Expands Stock Repurchase By 3M Shares, Totaling 4.1M Shares (HRC)
Monday, May 9, 2011 - 9:09am | 21Hill Rom (NYSE: HRC) Expands Stock Repurchase By 3M Shares, Totaling 4.1M Shares
-
Medtronic and Bayer HealthCare Expand International Alliance
Monday, May 9, 2011 - 9:06am | 46Medtronic, Inc. (NYSE: MDT) and Bayer HealthCare have expanded their international alliance to now include the United States and will work exclusively to develop innovative next generation diabetes management solutions for patients, state-of-the-art, wireless blood glucose meters worldwide.
-
Hill Rom Raises Dividend to $0.1125 from $0.1025 (HRC)
Monday, May 9, 2011 - 9:04am | 16Hill Rom (NYSE: HRC) Raises Dividend to $0.1125 from $0.1025.
-
Boston Scientific Begins U.S. and International Launch of Expect Endoscopic Ultrasound Aspiration Needle
Monday, May 9, 2011 - 8:31am | 71Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and international launch of its Expect™ Endoscopic Ultrasound Aspiration Needle, used for acquiring tissue samples for diagnosing and staging malignancies in organs adjacent to the gastrointestinal tract. The Expect Needle...